Vaderis Raises $152M to Lead Phase 3 Study in Rare Blood Vessel Disorder HHT on August 11, 2026 AKT Inhibitor Biological Science Disciplines Clinical Research engasertib EQT Goldman Sachs Hereditary hemorrhagic telangiectasia HHT Infrequent Phase 3 Series B TCGX VAD044 Vaderis Therapeutics Vascular Diseases +
Latigo targets $272M+ IPO to fund rival Nav1.8 pain drug to Vertex’s Journavx on August 04, 2026 Abdominoplasty (procedure) Acute onset pain Biotherapeutics Goldman Sachs IPO Jefferies Journavx Latigo Leerink Partners LTGO Nav1.8 inhibitor non-opioid pain drug Silver bunionectomy Suzetrigine +
Bristol Myers Squibb Hires Goldman Sachs Biotech Analyst Chris Shibutani as Chief Strategy Officer on June 13, 2025 Big Pharma Chris Shibutani corporate external partnerships Goldman Sachs Long-Term Strategy Myers squibb +
Ironwood Pharmaceuticals' Stock Plummets Following Layoffs and FDA Setback for Apraglutide on April 15, 2025 Biotechnology Goldman Sachs Ironwood Phase 3 Clinical Trials plunge regulatory hurdle Short Bowel Syndrome strategic alternatives United States Food and Drug Administration +